Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms

Table 1

Demographic and metabolic characteristics of study subjects.

Characteristic	Non-NAFLD (N = 49)	NAFLD (N = 49)
General
Gender, n (%)			0.832
Male	33 (67.3%)	31 (63.3%)
Female	16 (32.7%)	18 (36.7%)
Age, year	57.22 ± 12.33	58.88 ± 12.89	0.431
Duration of diabetes, year	9 (4, 15)	6 (0, 10)	0.042
BMI, kg/m2	26.12 (25.08, 28.3)	28.76 (26.93, 30.9)	<0.001
Biochemical markers
FBG, mmol/L	7.66 (6.38, 9.85)	9.99 (7.49, 12.88)	0.017
HbA1c, %	8 (6.8, 10.4)	10 (8.57, 11.4)	<0.001
LDL, mmol/L	2.25 ± 0.74	2.68 ± 0.87	0.012
HDL, mmol/L	0.96 (0.81, 1.1)	0.84 (0.72, 0.98)	0.009
ALT, IU/L	22 (17, 39)	25 (18, 42)	0.384
AST, IU/L	23 (17, 29)	21 (15, 33)	0.440
eGFR, ml/min/1.73 m^2	115.23 ± 51.74	121.59 ± 45.18	0.154
FT3, pmol/L	5.03 (4.52, 5.34)	4.76 (4.34, 5.28)	0.238
FT4, pmol/L	13.03 (11.33, 13.79)	14.17 (12.49, 16.07)	0.005
TSH, mIU/L	1.26 (0.9, 1.71)	1.94 (1.12, 2.95)	0.004
Use of hypoglycemic drugs
Insulin (N, %)	20 (40.8%)	21 (42.9%)	0.838
Metformin (N, %)	28 (57.1%)	29 (59.2%)	0.838
Thiazolidinediones (N, %)	2 (4.1%)	3 (6.1%)	0.646
Sulfonylureas/glinides (N, %)	3 (6.1%)	3 (6.1%)	1.000
Glucosidase inhibitors	11 (22.4%)	11 (22.4%)	1.000
SGLT2 inhibitors	21 (42.9%)	29 (59.2%)	0.106